Clinical Trials Logo

Steroid-Refractory Chronic GVHD clinical trials

View clinical trials related to Steroid-Refractory Chronic GVHD.

Filter by:
  • None
  • Page 1

NCT ID: NCT00472225 Active, not recruiting - Clinical trials for Steroid-Refractory Chronic GVHD

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Start date: May 2007
Phase: Phase 2
Study type: Interventional

Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic immunodeficiency etc. Thus, chronic GVHD can lead to debilitating complications such as joint contractures, blindness, end-stage lung disease, etc so that chronic GVHD has a major impact both on survival as well as quality of life. Although its pathogenesis is still poorly unclear, it has been reported since 2000 that B cell-mediated immunity may also contribute to development of chronic GVHD other than T cells. Thus, targeting against B cell may be a useful treatment strategy in the treatment of chronic GVHD. The purpose of this study is to determine whether rituximab, an anti-CD20 monoclonal kimeric antibody is effective in the treatment of chronic graft-versus-host disease (chronic GVHD) refractory to steroid.